Customer Reimbursement Webcast Features CMS Deputy Director Marc Hartstein

DANVERS, Mass. (Danvers, Mass., September 27, 2006)-Abiomed, Inc. (NASDAQ: ABMD) announced availability of its customer Webcast on the Centers for Medicare and Medicaid Services’ (CMS) Final Rule for the Inpatient Prospective Payment System (IPPS). The Webcast includes Marc Hartstein, Deputy Director of CMS’ Acute Care Division discussing the key initiatives of CMS for inpatient reimbursement and critical changes impacting hospitals.  As part of Abiomed’s expanded customer services offering, the Partnership in Healthcare Program, this educational session on the reimbursement changes effective on October 1, 2006 will now be available online at www.abiomed.com .

This webcast reviews important aspects of the CMS Final Rule, the daily Current Procedure Terminology (CPT) codes for care of Ventricular Assist Device (VAD) patients, and how to best incorporate these changes into hospital mechanical circulatory support programs.

Webcast presenters include:

• Marc Hartstein, Deputy Director, CMS, Acute Care Division

• Judith M. Hickey, President, Princeton Reimbursement Group

• Andrew Greenfield, Vice President, Abiomed

• Gwen Mayes, JD, Director, Government Relations & Reimbursement, Abiomed

“Abiomed is dedicated to providing the latest information on reimbursement and hospital economics for our customers. We are encouraged by the reimbursement changes we have seen, which are designed with improved patient outcomes in mind,” said Michael R. Minogue, Chairman, CEO and President of Abiomed. “We look forward to providing financial and clinical expertise to the growing number of hospitals looking to incorporate VAD recovery programs into their practices.”

ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. Abiomed currently manufactures and sells the AB5000™ Circulatory Support System and the BVS® 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. In Europe, Abiomed offers the IMPELLA® RECOVER® minimally invasive cardiovascular support systems under CE Mark approval. The IMPELLA® 5.0 and 2.5 are investigational devices limited by Federal Law solely to investigational use in the United States. Other IMPELLA devices are not yet available for sale in the United States. The Company's AbioCor® Implantable Replacement Heart is now available under a Humanitarian Device Exemption granted by the United States Food and Drug Administration. For additional information please visit: www.abiomed.com.

Contacts:

Daniel Sutherby	Liza Heapes
Abiomed, Inc.	Abiomed, Inc.
Chief Financial Officer	Media Relations
978-646-1812	978-646-1668
ir@abiomed.com	mediarelations@abiomed.com

FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.

###